Clinical Trial Update: Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 multi-dose escalation trial evaluating the safety and pharmacokinetics of SAR3419 as a single agent in relapsed/refractory B-cell non-Hodgkin lymphoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• SAR3419

Snippet

Sponsor: Sanofi | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED